Valuation: Autolus Therapeutics plc

Market Cap 495M 435M 412M 373M 701M 47.52B 705M 4.93B 1.9B 24.25B 1.86B 1.82B 77.92B P/E 2026 *
-2.31x
P/E 2027 * -2.73x
Enterprise Value 339M 298M 282M 256M 480M 32.54B 483M 3.38B 1.3B 16.61B 1.27B 1.25B 53.36B EV / Sales 2026 *
2.26x
EV / Sales 2027 * 2.17x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.27%
1 week-4.12%
Current month-20.85%
1 month-20.51%
3 months+15.53%
6 months+53.72%
Current year-6.53%
1 week 1.79
Extreme 1.79
2.05
1 month 1.79
Extreme 1.79
2.38
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2014-08-31
Chief Executive Officer 61 2016-02-29
Director of Finance/CFO 56 2023-08-06
Director TitleAgeSince
Chairman 61 2014-09-30
Director/Board Member 78 2014-07-31
Director/Board Member 71 2018-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Executive/Senior Manager

-6,713 0.0025%
6/29/26 Free

Director

79,167 0.0477%
3/18/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-4.12%+19.23%-22.82% 495M
-0.80%+14.07%+705.55%+96.75% 78.76B
-4.54%-5.75%+33.40%-9.86% 75.12B
+0.21%+0.87%-8.39%-27.31% 61.14B
-0.33%-0.80%-6.94%+173.15% 46.07B
+2.49%-0.14%-8.95%+33.71% 47.57B
+0.48%+4.39%+66.48%-11.30% 33.79B
+0.75%+0.14%+50.93%+112.97% 25.3B
-0.26%-6.98%+2.46%+150.72% 21.34B
+0.20%-1.83%+57.48%+96.96% 15.36B
Average -0.19%+0.40%+91.13%+59.29% 40.49B
Weighted average by Cap. -0.64%+2.03%+151.38%+54.23%

Financials

2026 *2027 *
Net sales 150M 132M 125M 113M 212M 14.38B 213M 1.49B 576M 7.34B 562M 550M 23.58B 192M 169M 160M 145M 273M 18.47B 274M 1.92B 740M 9.43B 722M 707M 30.29B
Net income -219M -192M -182M -165M -310M -21.01B -312M -2.18B -842M -10.72B -822M -804M -34.45B -185M -163M -154M -140M -263M -17.8B -264M -1.85B -713M -9.08B -696M -681M -29.18B
Net Debt -156M -137M -130M -118M -221M -14.98B -222M -1.55B -600M -7.64B -586M -573M -24.56B -77.38M -68.05M -64.35M -58.37M -110M -7.43B -110M -771M -298M -3.79B -291M -284M -12.18B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
26-09-28 US$1.860 +0.27% 1,399,645
26-09-25 US$1.855 -2.88% 1,383,522
26-09-24 US$1.910 -2.05% 1,819,211
26-09-23 US$1.950 -3.94% 1,442,556
26-09-22 US$2.030 +4.64% 1,569,963
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.860USD
Average target price
8.725USD
Spread / Average Target
+369.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock